This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • Genomic Biomarker Testing
      • PEACE-3 Trial
      • PROfound Trial
      • PSMAfore Trial
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • VISION Trial
    • mHSPC
      • ARANOTE Trial
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • nmCSPC
      • EMBARK Trial
    • PSMA PET Imaging
      • COBRA Trial
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
      • BOND-003 Cohort P
      • CORE-001 Study
      • CORE-008
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Health Policy
          • Health Policy
            Daniel D. Joyce, MD, MS
        • Bladder Cancer
          • Non-Muscle Invasive Bladder Cancer
            Ashish Kamat, MD
          • Muscle-Invasive Bladder Cancer
          • Advanced & Metastatic Bladder Cancer (mUC)
          • Trimodality Therapy
            Leslie Ballas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
        • Endourology
          • Endourology
            Jaime Landman, MD
      • Prostate Cancer
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • Decipher® Genomic Classifier
        • Imaging Center
          Phillip Koo, MD
        • mHSPC
          Neeraj Agarwal, FASCO, MD
        • nmCRPC
          Zachary Klaassen, MD, MSc
        • mCRPC Treatment
          A. Oliver Sartor, MD
        • mCRPC with Bone Metastasis
        • PSMA-Targeted Therapy
        • Advanced Prostate Cancer
          Zachary Klaassen, MD, MSc
      • Disparities: Social Determinants of Health
        • Disparities: Social Determinants of Health
          Samuel L. Washington III, MD, MAS
      • Translational Prostate Cancer
        • Translational Science in Prostate Cancer
          Andrea Miyahira, Ph.D
        • Women in Science
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • Testicular, Penile & Rare GU Malignances
        • Testicular Cancer
    • Functional Urology
      • Functional Urology
        Alan J. Wein, MD, PhD (hon.)
      • Urologic Catheters - CAUTI Challenges
  • Videos
    • Exclusives
      • Conferences
      • Disparities: Social Determinants of Health
      • Exclusive Collaborations
      • Health Policy in Urological Diseases
      • Independent Medical Education
      • Journal Clubs
      • Practice Guidelines Reviews
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Testicular Cancer
      • Endourology
    • Functional Urology
      • Men's Health
      • Pelvic Health
  • Actionable Clinical Data
    • Bladder Cancer
      • NMIBC with CIS: Evidence, Practice & Emerging Research
      • Risk-Stratified NMIBC Management
  • Trials in Progress
    • Prostate Cancer
      • Localized Prostate Cancer
        • CLARIFY
        • ESCAPE
        • FORT
        • NRG-GU 0101
        • RTIRE
      • High Risk BCR HSPC
        • ARASTEP
      • Oligometastatic Prostate Cancer
        • METANOVA
      • mHSPC
        • ARASEC
        • ASPIRE
        • MEVPRO-3
      • mCRPC
        • ECLIPSE
        • LEGION-100
        • MEVPRO-1 & 2
        • PROMISE
        • SECuRE
    • Bladder Cancer
      • PIVOT-006
    • Kidney Cancer
      • RadiCal
      • SAMURAI
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • SNMMI 2026
      • ASCO 2026
      • AUA 2026
      • APCCC 2026
      • PSMA and Beyond 2026
    • All Conferences
      • View All
  • PCF
  1. UroToday Home

UroToday Site Search

5 Results
Conference Coverage
APCCC 2026: What Is the Evidence for Using Metformin in Advanced Prostate Cancer?
(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a management and prevention of frequent side effects and modifying the metabolism session, and a presentation by Dr. Anthony Joshua discussing the evidence for using metformin in advanced prostate cancer. . It is important to note that 25% of deaths that occur after a diagnosis of mHSPC are non-cancer related and are most commonly secondary to cardiova...
Last updated May. 4, 2026
Abstract
Beyond Menopause: Ending the Inequality-Why Men with Prostate Cancer Still Lack Therapies for Hot Flushes - Beyond the Abstract
We are particularly pleased that European Urology chose to publish our editorial on hot flushes in men receiving androgen deprivation therapy (ADT) in its December issue. 1 Movember, the month dedicated to raising awareness for men’s health issues, has just ended. Publishing an editorial on vasomotor symptoms immediately afterwards sends a clear and, I think, important signal: putting men with prostate cancer and their everyday needs at the cen...
Last updated Jan. 28, 2026
Video
Hot Flushes – How Can We Help Our Patients? "Presentation" - Anthony Joshua
At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Anthony Joshua presents a comprehensive examination of hot flushes in prostate cancer patients undergoing androgen deprivation therapy. The presentation covers various management approaches from lifestyle modifications to pharmaceutical interventions like fezolinetant, while highlighting the challenges in treating hot flushes and emphasizing the need for better therapeutic option...
Last updated Feb. 4, 2025
Abstract
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Background and objective Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. . Here we present voting results for questions from APCCC 2024. Methods B...
Last updated Oct. 16, 2024
Conference Coverage
APCCC 2024: Hot Flushes – How Can We Help Our Patients?
(UroToday.com) The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a session on the identification, assessment, and management of side effects of systemic therapies, and a presentation by Dr. Anthony Joshua discussing how we can help our patients with hot flushes. The pathophysiology of side effects secondary to ADT is based on: . Suppression of testosterone, leading to erectile dysfunction, loss of muscle mass, loss...
Last updated Oct. 17, 2024
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2026 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free